Shares of Biopharmx Corp (NASDAQ:BPMX) gapped up before the market opened on Wednesday . The stock had previously closed at $0.28, but opened at $0.29. Biopharmx Corp shares last traded at $0.30, with a volume of 2,226,772 shares changing hands.
Several analysts have recently weighed in on BPMX shares. HC Wainwright set a $3.00 target price on Biopharmx Corp and gave the company a “buy” rating in a research note on Thursday, June 15th. Maxim Group restated a “buy” rating and set a $1.50 target price (down from $3.00) on shares of Biopharmx Corp in a research note on Wednesday, September 13th.
The company has a 50-day moving average price of $0.30 and a 200-day moving average price of $0.45. The stock’s market capitalization is $22.79 million.
Biopharmx Corp (NASDAQ:BPMX) last posted its earnings results on Wednesday, September 13th. The company reported ($0.06) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.06). The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.02 million. Biopharmx Corp had a negative net margin of 22,005.88% and a negative return on equity of 5,749.08%. Analysts anticipate that Biopharmx Corp will post ($0.24) EPS for the current fiscal year.
In related news, major shareholder Franklin Resources Inc purchased 250,000 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The shares were acquired at an average cost of $0.34 per share, with a total value of $85,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
A number of institutional investors and hedge funds have recently bought and sold shares of BPMX. Vanguard Group Inc. raised its holdings in Biopharmx Corp by 324.6% in the second quarter. Vanguard Group Inc. now owns 1,933,747 shares of the company’s stock worth $927,000 after purchasing an additional 1,478,338 shares during the period. Vivo Capital LLC grew its position in Biopharmx Corp by 10.0% in the second quarter. Vivo Capital LLC now owns 14,096,338 shares of the company’s stock valued at $6,752,000 after purchasing an additional 1,282,052 shares in the last quarter. Finally, Virtu KCG Holdings LLC grew its position in Biopharmx Corp by 366.2% in the second quarter. Virtu KCG Holdings LLC now owns 503,418 shares of the company’s stock valued at $241,000 after purchasing an additional 395,424 shares in the last quarter.
Biopharmx Corp Company Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.